Advertisement Banner
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
HealthNews
No Result
View All Result
Home Health Tech News

Unstable retinal thickening may lead to poor visual outcomes during anti-VEGF therapy

admin by admin
July 18, 2022
in News



Source/Disclosures

Published by:

occular surgery news logo

Source:

Chantarasorn Y, et al. Treatment outcome of wet age-related macular degeneration management in Thailand: The study report no. 2: The analysis of retinal fluid fluctuation. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.

Disclosures:
Chantarasorn reports no relevant financial disclosures.




ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — Unstable retinal thickening may contribute to substandard visual outcomes during anti-VEGF treatment, according to a speaker here.

“As we are all aware, apart from the inconsistency of retinal fluid, variability in foveal thickness during anti-VEGF treatment is associated with worse visual outcomes,” Yodpong Chantarasorn, MD, said at the American Society of Retina Specialists annual meeting.

Chantarasorn mug

Yodpong Chantarasorn

Chantarasorn and colleagues conducted a retrospective cohort study at five tertiary hospitals between January 2016 and December 2018 to determine predictive biomarkers associated with central subfield thickness fluctuation. A novel parameter, the fluid fluctuation index, was used to assess central subfield thickness variations in clinical practice.

In the 558 eyes analyzed, bevacizumab, aflibercept and ranibizumab accounted for 78.5%, 17.1% and 4.3% of anti-VEGFs used, respectively. Polypoidal choroidal vasculopathy occurred in 58% of the eyes, and 22.7% of eyes were lost to follow-up at 24 months.

Patients with greater fluid fluctuation showed worse best corrected visual acuity than patients with lower fluctuations, with an average difference of 10.7 letters at 12 months and 14 letters at 24 months (both P = .001).

The fluid fluctuation index offers an indirect and simple way to assess choroidal neovascularization activity and individualized responses to anti-VEGF medications, Chantarasorn said.

“Sufficient anti-VEGF therapy may be required in eyes at risk of retinal fluid fluctuation,” he said.




ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

American Society of Retina Specialists Meeting

American Society of Retina Specialists Meeting



Source link

Advertisement Banner
Previous Post

Antitrust Push in Healthcare Must Focus on ‘Human Impact’

Next Post

Will Omicron Subvariant BA.2.75 Be the Next COVID Threat?

Next Post

Will Omicron Subvariant BA.2.75 Be the Next COVID Threat?

Discussion about this post

Recommended

Tribute to One of Our Top Commenters

2 months ago

The Lies Behind Lab-Cultured Fake Meat

2 months ago

Don't Miss

Primal Fitness Coach Certification Program

August 18, 2022

Vuzix tries out smart glasses for emergency medical care in Japan

August 18, 2022

Use Of Sleep Medications Among Americans Declining In Recent Years

August 18, 2022

Mirena Approved for Pregnancy Prevention for Up to 8 Years

August 18, 2022

© 2022 Pharma News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.

Navigate Site

  • News
  • Medicine
  • Health Tech
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

© 2022 Pharma News Hubb All rights reserved.